Analyst Yun Zhong of Wedbush reiterated a Buy rating on CAMP4 Therapeutics Corporation, retaining the price target of $8.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Yun Zhong has given his Buy rating due to a combination of factors that highlight CAMP4 Therapeutics Corporation’s strategic focus and financial health. The company’s decision to concentrate on the CMP-002 program for SYNGAP1 mutation-related disorders is a significant strategic move, as it aligns with the ongoing GLP toxicology studies and the anticipated preliminary data by the end of 1Q26. This focus is expected to facilitate discussions with regulatory agencies and potentially lead to clinical trials in the second half of 2026.
Additionally, CAMP4’s financial position is robust, with $75.3 million in cash at the end of 3Q25, bolstered by a $50 million private placement. This financial runway is projected to last until 2027, with the possibility of extending it further upon approval for CMP-002’s clinical entry. The company’s proprietary RNA-based technology platform is seen as having strong potential to address a wide range of haploinsufficient diseases, reinforcing the Outperform rating and an $8 price target.
In another report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $7.00 price target.